Fig. 5: Activities of clinical drug candidates against NF54/iGP1_RE9Hulg8 stage V gametocytes in vitro. | Nature Communications

Fig. 5: Activities of clinical drug candidates against NF54/iGP1_RE9Hulg8 stage V gametocytes in vitro.

From: An all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs

Fig. 5: Activities of clinical drug candidates against NF54/iGP1_RE9Hulg8 stage V gametocytes in vitro.

Comparison of RE9H bioluminescence- and MitoTracker/gametocyte shape-based viability readouts for NF54/iGP1_RE9Hulg8 stage V gametocytes treated with clinical drug candidates. A Dose-response curves of MMV390048 and OZ439/artefenomel (left graph) and KAE609/cipargamin, KAF156/ganaplacide and SJ733 (right graph) tested against NF54/iGP1_RE9Hulg8 stage V gametocytes (day 12) using RE9H-catalysed bioluminescence as viability readout. MB was used as a positive control (identical data shown in both graphs). Values on the y-axis represent RLUs normalized to the mean signal emitted from cells exposed to the lowest drug concentration, obtained from n = 3 biological replicates (mean ± s.e.m.). B Dose-response curves of MMV390048 and OZ439/artefenomel (left graph) and KAE609/cipargamin, KAF156/ganaplacide and SJ733 (right graph) tested against NF54/iGP1_RE9Hulg8 stage V gametocytes (day 12) using MitoTracker signal/gametocyte shape as viability readout. MB has been used as a positive control (identical data shown in both graphs). Values on the y-axis represent normalized mean numbers of viable gametocytes obtained from n = 3 biological replicates (n = 2 biological replicates for OZ439/artefenomel and MMV390048) (mean ± s.e.m.). IC50 values and 95% confidence intervals (CI) are shown below the graphs.

Back to article page